


CURRICULUM VITAE

Name: Danny N Dhanasekaran



Email: danny-dhanasekaran@ouhsc.edu

Phone: +1 405-271-6850

Fax: +1 405-271-2507

Position: Samuel Noble Foundation Endowed Chair in Cancer Biology & Professor of Cell Biology, Director, SCC-COBRE & Center for Basic Cancer Research, Deputy Director for Basic Research

Institution: Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Location: Oklahoma City, OK 73104, USA

Education: Ph.D in Biochemistry, Indian Institute of Science, Bangalore, India

Representative Careers:

- 1985-1988 Research Associate, Dept. of Pharmacology, University of Wisconsin Medical School, Madison, WI
- 1988-1990 Senior Research Associate, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, USA
- 1990-1992 Assistant Scientist, Dept. of Pharmacology, University of Wisconsin Medical School, Madison, WI, USA
- 1992-1998 Assistant Professor, Department of Biochemistry, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA, USA
- 1998 - 2008 Associate Professor, Department of Biochemistry, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA
- 2008-2009 Professor, Department of Biochemistry, Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA
- 2009-2012 WCU Visiting Professor, Seoul National University, Seoul, S. Korea
- 2009-present Director, Center for Basic Cancer Research; Deputy Director for Basic Research, Stephenson Cancer Center, Professor, Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104

Specialty & Present Interest:

Ovarian and Pancreatic Cancer research, Signaling networks, Non-coding RNAs

Representative papers (up to 5):

1. Radhakrishnan R, Ha JH, Jayaraman M, Liu J, Moxley KM, Isidoro C, Sood AK, Song YS, Dhanasekaran DN. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts. *Cancer Lett.* 2019; 442:464-474. PMID:30503552

2. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley KM, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. *Cancer Res.* 2018; 78(8):1923-1934. PMID: 29386184.
3. Kim S, Lee M, Dhanasekaran DN, Song YS. Activation of LXR α/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer. *BMC Cancer.* 2018;18:1232. doi: 10.1186/s12885-018-5152-5. PMID: 30526541
4. Jayaraman M, Radhakrishnan R, Mathews CA, Yan M, Husain S, Moxley KM, Song YS, Dhanasekaran DN. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. *Genes Cancer.* 2017; 8:566-576. PMID: 28740575
5. Ferraresi A, Titone R, Follo C, Castiglioni A, Chiorino G, Dhanasekaran DN, Isidoro C. The protein restriction mimetic Resveratrol is an autophagy inducer stronger than amino acid starvation in ovarian cancer cells. *Mol Carcinog.* 2017; 56: 2681-2691. PMID: 28856729